|
1
|
Ito A, Shintaku I, Satoh M, Ioritani N,
Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, et al:
Prospective randomized phase II trial of a single early
intravesical instillation of pirarubicin (THP) in the prevention of
bladder recurrence after nephroureterectomy for upper urinary tract
urothelial carcinoma: The THP Monotherapy Study Group Trial. J Clin
Oncol. 31:1422–1427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomita N, Kodama F, Tsuyama N, Sakata S,
Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H,
et al: Biweekly THP-COP therapy for newly diagnosed peripheral
T-cell lymphoma patients. Hematol Oncol. 33:9–14. 2015. View Article : Google Scholar
|
|
3
|
Shimomura Y, Baba R, Watanabe A, Horikoshi
Y, Asami K, Hyakuna N, Iwai A, Matsushita T, Yamaji K, Hori T, et
al Japanese Childhood Cancer and Leukemia Study Group (JCCLSG):
Assessment of late cardiotoxicity of pirarubicin (THP) in children
with acute lymphoblastic leukemia. Pediatr Blood Cancer.
57:461–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Tang JH, Huang XE and Li CG:
Clinical comparison on the safety and efficacy of
fluorouracil/pirarubicin/cyclophosphamide (FPC) with
fluorouracil/epirubicin/cyclophosphamide (FEC) as postoperative
adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev.
12:1795–1798. 2011.
|
|
5
|
du Bois A, Meerpohl HG, Madjar H, Spinner
D, Dall P, Pfisterer J and Bauknecht T: phase II study of
pirarubicin combined with cisplatin in recurrent ovarian cancer. J
Cancer Res Clin Oncol. 120:173–178. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao H, Yao Y, Wang Z, Lin F, Sun Y and
Chen P: Therapeutic effect of pirarubicin-based chemotherapy for
osteosarcoma patients with lung metastasis. J Chemother.
22:119–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hyun SY, Cheong JW, Kim SJ, Min YH, Yang
DH, Ahn JS, Lee WS, Ryoo HM, Do YR, Lee HS, et al: High-dose
etoposide plus granulocyte colony-stimulating factor as an
effective chemomobilization regimen for autologous stem cell
transplantation in patients with non-Hodgkin Lymphoma previously
treated with CHOP-based chemotherapy: A study from the Consortium
for Improving Survival of Lymphoma. Biol Blood Marrow Transplant.
20:73–79. 2014. View Article : Google Scholar
|
|
8
|
Asakuma M, Yamamoto M, Wada M, Ryuge S,
Katono K, Yokoba M, Fukui T, Takakura A, Otani S, Maki S, et al:
Phase I trial of irinotecan and amrubicin with granulocyte
colony-stimulating factor support in extensive-stage small-cell
lung cancer. Cancer Chemother Pharmacol. 69:1529–1536. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gudi R, Krishnamurthy M and Pachter BR:
Astemizole in the treatment of granulocyte colony-stimulating
factor-induced bone pain. Ann Intern Med. 123:236–237. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chihara G, Hamuro J, Maeda YY, Shiio T,
Suga T, Takasuka N and Sasaki T: Antitumor and
metastasis-inhibitory activities of lentinan as an immunomodulator:
An overview. Cancer Detect Prev Suppl. 1:423–443. 1987.PubMed/NCBI
|
|
11
|
Liu YH, Ma SD, Fu QJ, Zhao LY, Li Y, Wang
HQ and Li MC: Effect of lentinan on membrane-bound protein
expression in splenic lymphocytes under chronic low-dose radiation.
Int Immunopharmacol. 22:505–514. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attia SM, Harisa GI, Abd-Allah AR, Ahmad
SF and Bakheet SA: The influence of lentinan on the capacity of
repair of DNA damage and apoptosis induced by paclitaxel in mouse
bone marrow cells. J Biochem Mol Toxicol. 27:370–377. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Joo SY, Song YA, Park YL, Myung E, Chung
CY, Park KJ, Cho SB, Lee WS, Kim HS, Rew JS, et al:
Epigallocatechin-3-gallate inhibits LPS-induced NF-κB and MAPK
signaling pathways in bone marrow-derived macrophages. Gut Liver.
6:188–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Liu Y, Wang L, Li Z and Ma X:
Unfractionated heparin attenuates LPS-induced IL-8 secretion via
PI3K/Akt/NF-κB signaling pathway in human endothelial cells.
Immunobiology. 220:399–405. 2015. View Article : Google Scholar
|
|
15
|
Mannello F, Ligi D, Canale M and Raffetto
JD: Sulodexide down-regulates the release of cytokines, chemokines,
and leukocyte colony stimulating factors from human macrophages:
Role of glycosaminoglycans in inflammatory pathways of chronic
venous disease. Curr Vasc Pharmacol. 12:173–185. 2014. View Article : Google Scholar
|
|
16
|
Lee KY, Suh BG, Kim JW, Lee W, Kim SY, Kim
YY, Lee J, Lim J, Kim M, Kang CS, et al: Varying expression levels
of colony stimulating factor receptors in disease states and
different leukocytes. Exp Mol Med. 32:210–215. 2000. View Article : Google Scholar
|
|
17
|
Kamezaki K, Shimoda K, Numata A, Haro T,
Kakumitsu H, Yoshie M, Yamamoto M, Takeda K, Matsuda T, Akira S, et
al: Roles of Stat3 and ERK in G-CSF signaling. Stem Cells.
23:252–263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davis BK: Isolation, culture, and
functional evaluation of bone marrow-derived macrophages. Methods
Mol Biol. 1031:27–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salva S, Marranzino G, Villena J, Agüero G
and Alvarez S: Probiotic Lactobacillus strains protect against
myelosuppression and immunosuppression in cyclophosphamide-treated
mice. Int Immunopharmacol. 22:209–221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng SE, Xiong S, Lin F, Qiao GL, Feng T,
Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits
multidrug-resistant osteosarcoma cell proliferation through
induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin.
33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Munck JN, Rougier P, Chabot GG, Ramirez
LH, Bognel C, Lumbroso J, Herait P, Elias D, Lasser P and Gouyette
A: Phase I and pharmacological study of intra-arterial hepatic
administration of pirarubicin in patients with advanced hepatic
metastases. Eur J Cancer. 30A:289–294. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baldo BA: Side effects of cytokines
approved for therapy. Drug Saf. 37:921–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ina K, Kataoka T and Ando T: The use of
lentinan for treating gastric cancer. Anticancer Agents Med Chem.
13:681–688. 2013. View Article : Google Scholar :
|
|
24
|
Fehér J, Chihara G, Vallent K, Deák G,
Blázovics A, Gergely P and Kaneko Y: Effect of lentinan on
superoxide dismutase enzyme activity in vitro. Immunopharmacol
Immunotoxicol. 11:55–61. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sridhar KS, Hussein AM, Benedetto P,
Ardalan B, Savaraj N and Richman SP: Phase II trial of
4′-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck
carcinoma. Cancer. 70:1591–1597. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kleeberg UR, Reichel L, Wander HE, Beyer
JH, Essers U, Fiebig HH and Edler L: Phase II study of pirarubicin
in metastatic breast cancer. Onkologie. 13:175–179. 1990.PubMed/NCBI
|
|
27
|
Rapoport BL and Falkson G: phase II
clinical study of pirarubicin in hormone resistant prostate cancer.
Invest New Drugs. 10:119–121. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Wang M, Chen J, Tang Y, Dou J, Yu
J, Xi T and Zhou C: A polysaccharide from Strongylocentrotus nudus
eggs protects against myelosuppression and immunosuppression in
cyclophosphamide-treated mice. Int Immunopharmacol. 11:1946–1953.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu Q, Nie SP, Wang JQ, Liu XZ, Yin PF,
Huang DF, Li WJ, Gong DM and Xie MY: Chemoprotective effects of
Ganoderma atrum polysaccharide in cyclophosphamide-induced mice.
Int J Biol Macromol. 64:395–401. 2014. View Article : Google Scholar
|
|
30
|
Bhatia S, Rathee P, Sharma K, Chaugule BB,
Kar N and Bera T: Immuno-modulation effect of sulphated
polysaccharide (porphyran) from Porphyra vietnamensis. Int J Biol
Macromol. 57:50–56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu X, Pan C, Zhang L and Ashida H:
Immunomodulatory beta-glucan from Lentinus edodes activates
mitogen-activated protein kinases and nuclear factor-kappaB in
murine RAW 264.7 macrophages. J Biol Chem. 286:31194–31198. 2011.
View Article : Google Scholar : PubMed/NCBI
|
